Dr. Leath Discusses Surgical Cytoreduction in Ovarian Cancer

Charles A. (Trey) Leath III, MD
Published: Wednesday, Aug 16, 2017



Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses surgical cytoreduction in ovarian cancer.

With recently emerging data, oncologists are better equipped to identify patients who do not need primary cytroreduction. Additionally, Leath says that oncologists now know what to do—and what not to do—at the time of surgery for their patients with ovarian cancer.
 


Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses surgical cytoreduction in ovarian cancer.

With recently emerging data, oncologists are better equipped to identify patients who do not need primary cytroreduction. Additionally, Leath says that oncologists now know what to do—and what not to do—at the time of surgery for their patients with ovarian cancer.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x